DelveInsight’s, “Atrial Fibrillation Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the Atrial Fibrillation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atrial Fibrillation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Atrial Fibrillation Treatment Landscape @ https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight

Key Takeaways from the Atrial Fibrillation Pipeline Report

• On June 05, 2026- Janssen Research & Development LLC initiated a phase 3 study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
• DelveInsight’s Atrial Fibrillation pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Atrial Fibrillation treatment.
• The leading Atrial Fibrillation Companies such as HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
• Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.

Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments @ Atrial Fibrillation Clinical Trials Assessment

Atrial Fibrillation Overview

Atrial Fibrillation (AFib) is the most common type of arrhythmia, characterized by irregular and often rapid heartbeats. This condition arises from abnormal electrical impulses in the atria, the upper chambers of the heart, leading to ineffective atrial contractions. As a result, blood flow within the heart becomes turbulent, increasing the risk of clot formation, which can lead to stroke or other cardiovascular complications. AFib can be paroxysmal (occasional), persistent, or permanent, depending on its duration and response to treatment. Patients with AFib may experience a range of symptoms, from mild to severe.

Atrial Fibrillation Emerging Drugs Profile

• Etripamil: Milestone Pharmaceuticals Inc.

Etripamil is an investigational, fast-acting L-type calcium channel blocker delivered as a nasal spray, developed for on-demand, self-administered treatment of paroxysmal supraventricular tachycardia (PSVT). As Milestone’s lead candidate, Etripamil is designed to offer rapid symptom relief outside of a clinical setting, potentially transforming the management of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR). It is currently in Phase III development for AFib-RVR.

• HBI-3000: HUYA Bioscience

HBI-3000 is a multi-ion channel blocker with in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr being developed by HUYABIO International for the conversion of recent onset atrial fibrillation. The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing. Data from the first in human Phase I trial of the IV formulation were presented during a poster session at the American Heart Association 2019 annual meeting. Currently, the drug is in the Phase II stage of its development for the treatment of Atrial Fibrillation.

The Atrial Fibrillation Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
• Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline @ Atrial Fibrillation Unmet Needs

Atrial Fibrillation Companies

HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Atrial Fibrillation Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives

Scope of the Atrial Fibrillation Pipeline Report

• Coverage- Global
• Atrial Fibrillation Companies- HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
• Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
• Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Atrial Fibrillation: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atrial Fibrillation– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Etripamil: Milestone Pharmaceuticals Inc.
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. HBI-3000: HUYA Bioscience
12. Preclinical and Discovery Stage Products
13. Drug Name: Company Name
14. Inactive Products
15. Atrial Fibrillation Key Companies
16. Atrial Fibrillation Key Products
17. Atrial Fibrillation- Unmet Needs
18. Atrial Fibrillation- Market Drivers and Barriers
19. Atrial Fibrillation- Future Perspectives and Conclusion
20. Atrial Fibrillation Analyst Views
21. Atrial Fibrillation Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight